The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse.
Cannabinoid CB1 antagonists decrease self-administration of palatable food and several abused drugs in animals and modulate extinction of conditioned fear responses. Less is known, however, about whether and how CB1 antagonists might modulate the extinction of appetitive behavior. Therefore, this study examined the effects of the CB1 receptor antagonist rimonabant (SR141716) during extinction of responding maintained either by cocaine or by palatable foods (corn oil or Ensure), as well as responding elicited by stimulus cues that had been paired with the presentation of cocaine (i.e., cue-induced reinstatement) or a prime (presentation of cocaine or food). The effect of rimonabant on high rate responding in water-deprived mice trained to self-administer water was also examined. In mice self-administering cocaine, rimonabant attenuated cue-induced reinstatement of cocaine self-administration, the initial burst of responding during cocaine extinction and responding during spontaneous recovery. In mice self-administering corn oil, rimonabant decreased responding during extinction and also attenuated responding that had been reinstated by a priming presentation of corn oil. Moreover, mice treated with rimonabant required fewer daily sessions to reach criterion for extinction of cocaine-maintained responding than vehicle treated mice. Also, rimonabant had no effect on the rate of operant responding in mice trained to respond for water under an FR5 schedule of reinforcement. Taken together, these data suggest that in addition to attenuating the primary reinforcing effects of both palatable foods and drugs of abuse, CB1 receptor antagonism can attenuate context and cue reactivity during extinction learning and potentially enhance extinction learning in this way.
Ward
Sara Jane
SJ
Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA 19140, United States. saraward@temple.edu
Rosenberg
Marisa
M
Dykstra
Linda A
LA
Walker
Ellen A
EA
D000818:Animals; D016739:Behavior, Addictive / Q000188:drug therapy; D003042:Cocaine / Q000008:administration & dosage*; D019970:Cocaine-Related Disorders / Q000188:drug therapy / Q000517:prevention & control*; D003216:Conditioning, Operant / Q000187:drug effects; D003314:Corn Oil / Q000008:administration & dosage; D003463:Cues; D019422:Dietary Sucrose / Q000008:administration & dosage; D004195:Disease Models, Animal; D005108:Extinction, Psychological / Q000187:drug effects*; D005526:Food, Formulated; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D012008:Recurrence; D012055:Reinforcement Schedule; D000077285:Rimonabant; D012646:Self Administration / Q000523:psychology*; D014867:Water / Q000008:administration & dosage
D019422:Dietary Sucrose; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D014867:Water; C082131:Ensure formulated food; D003314:Corn Oil; D003042:Cocaine; D000077285:Rimonabant
NIDA Res Monogr. 1993;137:73-95
8289929
J Appl Behav Anal. 1995 Spring;28(1):93-4
16795857
Psychopharmacology (Berl). 2007 Apr;191(2):223-31
17211653
Eur J Pharmacol. 2003 Sep 23;477(3):213-7
14522359
Psychopharmacology (Berl). 2005 May;179(2):452-60
15821957
Behav Res Ther. 1992 May;30(3):235-41
1586360
Psychopharmacology (Berl). 2006 Nov;188(4):641-9
16947018
Psychopharmacology (Berl). 2003 Feb;165(4):370-7
12447606
J Comp Physiol Psychol. 1956 Aug;49(4):381-91
13345917
Behav Pharmacol. 2005 Sep;16(5-6):381-8
16148442
Trends Pharmacol Sci. 2005 Aug;26(8):420-6
15992935
Neuropsychopharmacology. 2008 Jun;33(7):1735-45
17728698
Exp Neurol. 1963 Jan;7:65-75
14017412
Psychopharmacology (Berl). 2003 Jul;168(1-2):21-30
12695875
Eur J Pharmacol. 2000 Sep 15;404(1-2):175-9
10980277
Psychopharmacology (Berl). 2003 Jul;168(1-2):164-169
12669182
Learn Mem. 2008 Oct 28;15(11):806-9
18957525
Psychopharmacology (Berl). 2008 Sep;199(4):593-603
18488200
Pharmacol Rep. 2006 Nov-Dec;58(6):806-19
17220538
Behav Pharmacol. 2002 Sep;13(5-6):451-63
12394421
Nat Med. 2001 Oct;7(10):1151-4
11590440
Learn Mem. 2004 Sep-Oct;11(5):611-6
15466316
J Pharmacol Exp Ther. 2003 Jul;306(1):93-102
12660305
Psychopharmacology (Berl). 1997 Jul;132(1):104-6
9272766
Neuropsychopharmacology. 2009 Aug;34(9):2072-80
19322169
Psychopharmacology (Berl). 1999 Nov;147(1):22-4
10591861
Eur J Pharmacol. 2005 Mar 7;510(1-2):69-74
15740726
Pharmacol Rev. 2007 Jun;59(2):151-84
17540905
Addict Behav. 1990;15(4):355-65
2248109
Eur J Neurosci. 2005 Apr;21(8):2243-51
15869521
J Pharmacol Exp Ther. 2008 May;325(2):567-76
18256173
Psychopharmacology (Berl). 2005 Jun;179(4):863-72
15619104
Mol Neurobiol. 2007 Aug;36(1):92-101
17952654
Neuropsychopharmacology. 2007 Dec;32(12):2592-600
17392737
Mol Psychiatry. 2007 Feb;12(2):120-50
17160066
Biol Psychiatry. 2002 Nov 15;52(10):976-86
12437938
Physiol Behav. 2008 Mar 18;93(4-5):666-70
18076956
J Clin Psychiatry. 1988 Feb;49 Suppl:17-22
3276670
Neuroscience. 2007 Jun 8;146(4):1484-94
17449185
Brain Res. 2003 May 23;973(1):99-106
12729958
Nature. 2002 Aug 1;418(6897):530-4
12152079
Neuropsychopharmacology. 2004 Aug;29(8):1470-8
15085091
Neuropsychopharmacology. 2005 Sep;30(9):1670-80
15742004